Cited 0 times in
Inhibition of TNFalpha-interacting protein alpha (Tipalpha)-associated gastric carcinogenesis by BTG2(/TIS21) via downregulating cytoplasmic nucleolin expression
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Devanand, P | - |
dc.contributor.author | Oya, Y | - |
dc.contributor.author | Sundaramoorthy, S | - |
dc.contributor.author | Song, KY | - |
dc.contributor.author | Watanabe, T | - |
dc.contributor.author | Kobayashi, Y | - |
dc.contributor.author | Shimizu, Y | - |
dc.contributor.author | Hong, SA | - |
dc.contributor.author | Suganuma, M | - |
dc.contributor.author | Lim, IK | - |
dc.date.accessioned | 2019-11-13T00:17:57Z | - |
dc.date.available | 2019-11-13T00:17:57Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 1226-3613 | - |
dc.identifier.uri | http://repository.ajou.ac.kr/handle/201003/16806 | - |
dc.description.abstract | To understand the regulation of Helicobacter pylori (H. pylori)-associated gastric carcinogenesis, we examined the effect of B-cell translocation gene 2 (BTG2) expression on the biological activity of Tipalpha, an oncoprotein secreted from H. pylori. BTG2, the human ortholog of mouse TIS21 (BTG2(/TIS21)), has been reported to be a primary response gene that is transiently expressed in response to various stimulations. Here, we report that BTG2 is constitutively expressed in the mucous epithelium and parietal cells of the gastric gland in the stomach. Expression was increased in the mucous epithelium following H. pylori infection in contrast to its loss in human gastric adenocarcinoma. Indeed, adenoviral transduction of BTG2(/TIS21) significantly inhibited Tipalpha activity in MKN-1 and MGT-40, human and mouse gastric cancer cells, respectively, thereby downregulating tumor necrosis factor-alpha (TNFalpha) expression and Erk1/2 phosphorylation by reducing expression of nucleolin, a Tipalpha receptor. Chromatin immunoprecipitation proved that BTG2(/TIS21) inhibited Sp1 expression and its binding to the promoter of the nucleolin gene. In addition, BTG2(/TIS21) expression significantly reduced membrane-localized nucleolin expression in cancer cells, and the loss of BTG2(/TIS21) expression induced cytoplasmic nucleolin availability in gastric cancer tissues, as evidenced by immunoblotting and immunohistochemistry. Higher expression of BTG2 and lower expression of nucleolin were accompanied with better overall survival of poorly differentiated gastric cancer patients. This is the first report showing that BTG2(/TIS21) inhibits nucleolin expression via Sp1 binding, which might be associated with the inhibition of H. pylori-induced carcinogenesis. We suggest that BTG2(/TIS21) is a potential inhibitor of nucleolin in the cytoplasm, leading to inhibition of carcinogenesis after H. pylori infection. | - |
dc.language.iso | en | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Bacterial Proteins | - |
dc.subject.MESH | Biomarkers, Tumor | - |
dc.subject.MESH | Cell Line, Tumor | - |
dc.subject.MESH | Cell Transformation, Neoplastic | - |
dc.subject.MESH | Disease Models, Animal | - |
dc.subject.MESH | Gastric Mucosa | - |
dc.subject.MESH | Gene Expression Regulation, Neoplastic | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immediate-Early Proteins | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Mice | - |
dc.subject.MESH | Models, Biological | - |
dc.subject.MESH | Phosphoproteins | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Promoter Regions, Genetic | - |
dc.subject.MESH | Protein Binding | - |
dc.subject.MESH | RNA-Binding Proteins | - |
dc.subject.MESH | Sp1 Transcription Factor | - |
dc.subject.MESH | Stomach Neoplasms | - |
dc.subject.MESH | Tumor Suppressor Proteins | - |
dc.title | Inhibition of TNFalpha-interacting protein alpha (Tipalpha)-associated gastric carcinogenesis by BTG2(/TIS21) via downregulating cytoplasmic nucleolin expression | - |
dc.type | Article | - |
dc.identifier.pmid | 29472702 | - |
dc.identifier.url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903828/ | - |
dc.contributor.affiliatedAuthor | 임, 인경 | - |
dc.type.local | Journal Papers | - |
dc.identifier.doi | 10.1038/emm.2017.281 | - |
dc.citation.title | Experimental & molecular medicine | - |
dc.citation.volume | 50 | - |
dc.citation.number | 2 | - |
dc.citation.date | 2018 | - |
dc.citation.startPage | e449 | - |
dc.citation.endPage | e449 | - |
dc.identifier.bibliographicCitation | Experimental & molecular medicine, 50(2). : e449-e449, 2018 | - |
dc.identifier.eissn | 2092-6413 | - |
dc.relation.journalid | J012263613 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.